Trial record 1 of 1 for:
An Open Label Study of FT218 in Subjects With Narcolepsy (RESTORE)
An Open Label Study of FT218 in Subjects With Narcolepsy (RESTORE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04451668 |
|
Recruitment Status :
Active, not recruiting
First Posted : June 30, 2020
Last Update Posted : June 14, 2022
|
Sponsor:
Avadel
Information provided by (Responsible Party):
Avadel
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
An Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Narcolepsy Cataplexy Excessive Daytime Somnolence Sleep Disorder Sleep Disturbance Sleep Wake Disorders | Drug: FT218 | Phase 3 |
This study will enroll subjects with narcolepsy, either NT1 or NT2, who completed the FT218 Phase 3 REST-ON study or eligible subjects with narcolepsy currently receiving a stable dose of twice nightly sodium oxybate IR or mixed salts oxybate (regardless of whether they participated in the REST-ON study), or subjects who are naïve to oxybate therapy (i.e., FT218, twice nightly sodium oxybate IR or mixed salts oxybate). Following a screening period, subjects who meet the entry criteria will be enrolled into the study. Subjects who completed the FT218 Phase 3 REST-ON study will initiate treatment with FT218 at 4.5 g and will follow a titration schedule up to the highest tolerate dose (up to 9 g), or the dose deemed effective by the investigator. Subjects previously maintained on twice nightly sodium oxybate IR will initiate FT218 treatment at a dose equivalent or closest to the total gram dose of twice-nightly sodium oxybate IR and then titrate up or down, in accord with safety and effectiveness as determined by the investigator.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 175 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Open label treatment with FT218 (once nightly sodium oxybate extended release) |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR |
| Actual Study Start Date : | June 12, 2020 |
| Estimated Primary Completion Date : | June 2023 |
| Estimated Study Completion Date : | June 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Narcolepsy
MedlinePlus related topics:
Club Drugs
Drug Information available for:
Sodium Oxybate
| Arm | Intervention/treatment |
|---|---|
|
Experimental: FT218
once nightly sodium oxybate extended release oral solution (FT218)
|
Drug: FT218
once nightly sodium oxybate extended release |
Primary Outcome Measures :
- Incidence of treatment-related adverse events [ Time Frame: 24 months ]Assess the long-term safety and tolerability of FT218 by the number of participants experiencing treatment-related adverse events
- Incidence of clinically significant changes in vital signs [ Time Frame: 24 months ]Assess the long-term safety and tolerability of FT218 by the number of participants experiencing clinically significant changes in vital signs
- Incidence of clinically significant changes in laboratory test results [ Time Frame: 24 months ]Assess the long-term safety and tolerability of FT218 by the number of participants experiencing clinically significant changes in laboratory test results
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects receiving a stable doses of twice-nightly sodium oxybate IR or mixed salts oxybate for at least 4 weeks and are willing to switch to FT218
- Subjects who completed the CLFT218-1501 REST-ON Study in a compliant manner and for whom the Investigator determines would receive benefit from treatment with FT218 and have not started treatment with twice nightly sodium oxybate IR or mixed salts oxybate
- Are treatment naïve to any oxybate therapy (i.e. FT218, twice nightly sodium oxybate IR or mixed salts oxybate)
- Subjects have a diagnosis of narcolepsy, either confirmed prior to the REST-ON study or as confirmed by the Investigator as defined by the International Classification of Sleep Disorders 3 criteria (AASM 2014)
- Willing and able to give written informed consent for study participation. Young adults (16 and 17 years old) who have not reached the age of majority must be capable of giving assent in addition to consent from a legally authorized guardian, as required by local laws and regulations.
Exclusion Criteria:
- Subjects that terminated the CLFT218-1501 REST-ON Study prior to completing Visit 8
- Any use of the following medications during the study: Anticonvulsants, Clonidine, Hypnotics, Anxiolytics, Sedating antihistamines, Antipsychotics, Other experimental medications designed to treat narcolepsy, cataplexy or any other condition, or other medications with significant sedating effects/CNS depressant effects are prohibited for REST-ON and naive patients. Patients on twice nightly sodium oxybate IR on medications in classes listed above may be eligible for enrollment if the subject has been on a stable dose of the prohibited medication in combination with a stable dose of twice nightly sodium oxybate or mixed salts oxybate for at least three months and has demonstrated no AEs, intolerance, or interactions AND is approved to participate by the Medical Monitor. Sedative hypnotics are prohibited regardless.)
- A diagnosis of sleep apnea where AHI is ≥15 and/or current use of CPAP or other devices for sleep apnea.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04451668
Locations
Show 29 study locations
Sponsors and Collaborators
Avadel
| Responsible Party: | Avadel |
| ClinicalTrials.gov Identifier: | NCT04451668 |
| Other Study ID Numbers: |
CLFT218-1901 |
| First Posted: | June 30, 2020 Key Record Dates |
| Last Update Posted: | June 14, 2022 |
| Last Verified: | June 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Narcolepsy Sleep Wake Disorders Parasomnias Dyssomnias Cataplexy Disorders of Excessive Somnolence Disease |
Sleepiness Pathologic Processes Nervous System Diseases Neurologic Manifestations Mental Disorders Sleep Disorders, Intrinsic |